EMAIL THIS PAGE TO A FRIEND

Best practice & research. Clinical haematology

Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?


PMID 23200547

Abstract

Invasive fungal infections (IFIs) are difficult to diagnose, especially early in the course of infection when antifungal therapy is most effective. There are two commercially available biomarker assays useful for detection of the IFIs most commonly seen in patients with hematologic malignancies, the galactomannan and beta glucan assays. The former is specific for aspergillosis, the latter positive for not only Aspergillus and Candida species, but several other clinically relevant fungal pathogens as well. Both have good assay performance characteristics, provide rapid test results, are widely available, can be assayed non-invasively, and are positive early in the course of infection, often before onset of signs and symptoms of infection. Adoption of these assays into clinical practice has led to reduced need to perform invasive procedures to obtain deep tissue to establish the diagnosis of invasive fungal infections. Improved survival rates from aspergillosis are, in part, due to earlier detection of infection and earlier therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

48230 D-Galacto-D-mannan from Ceratonia siliqua, ~95% (HPLC)